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Abstract 23 
One of the most rapidly increasing human public health problems is obesity, whose sequelae 24 
like type-2 diabetes, represent continuously worsening, life-long conditions. Over the last 15 25 
years, data have begun to emerge from human and more frequently, mouse studies, that 26 
support the idea that parasitic worm infection can protect against this condition. We have 27 
therefore investigated the potential of two synthetic small molecule analogues (SMAs) of the 28 
anti-inflammatory Acanthocheilonema viteae product ES-62, to protect against metabolic 29 
dysfunction in a C57BL/6J mouse model of high calorie-induced obesity. We found weekly 30 
subcutaneous administration of the SMAs in combination (1 g of each), starting one week 31 
before continuous exposure to high calorie diet (HCD), decreased fasting glucose levels and 32 
reversed the impaired glucose clearance observed in male mice, when measured at 33 
approximately 7 and 13 weeks after exposure to HCD. Fasting glucose levels were also 34 
improved in male mice fed a HCD for some 38 weeks when given SMA-treatment 13 weeks 35 
after the start of HCD, indicating an SMA-therapeutic potential. For the most part, protective 36 
effects were not observed in female mice. SMA treatment also conferred protection against 37 
each of reduced ileum villus length and liver fibrosis, but more prominently in female mice. 38 
Previous studies in mice indicate that protection against metabolic dysfunction is usually 39 
associated with polarisation of the immune system towards a type-2/anti-inflammatory 40 
direction but our attempts to correlate improved metabolic parameters with such changes 41 
were unsuccessful. Further analysis will therefore be required to define mechanism of action. 42 
Nevertheless, overall our data clearly show the potential of the drug-like SMAs as a 43 
preventative or treatment for metabolic dysregulation associated with obesity. 44 
 45 
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1. Introduction 48 
The world is experiencing an obesity epidemic: over a third of the world’s adult population 49 
are defined as obese or overweight and this number is on the rise [1]. Obesity greatly 50 
increases the risk of developing enduring disease morbidities such as insulin resistance, type-51 
2 diabetes, metabolic syndrome, depression, cardiovascular disease and cancer, as these 52 
pathologies are promoted by the chronic, low-grade inflammation commonly associated with 53 
this condition. Such inflammation reflects that the stress on adipose tissue skews the immune 54 
system towards a type-1 response characterised by M1-like macrophages, neutrophils and 55 
pro-inflammatory cytokines, resulting in a vicious cycle involving the release of free fatty 56 
acids and pro-inflammatory markers such as TNF- and IL-6 that drives dysregulation of 57 
immunometabolic networks and ultimately insulin resistance [2-4]. By contrast, a 58 
predominantly type-2 inflammatory response involving eosinophils and alternatively 59 
activated (M2-like) macrophages (AAMs) has been shown to be important for the 60 
maintenance of healthy adipose tissue [4-6]. 61 
 62 
Parasitic helminths represent a group of organisms that generally induce a strong, type-2 63 
immune response in their hosts, that is characterised by increases in eosinophils, AAMs and 64 
mast cells and the production of cytokines such as IL-4 and IL-5. In addition, this response is 65 
often accompanied by a regulatory component which is associated for example, with the 66 
production of IL-10 and expansion of regulatory T and B cells (reviewed in [7]). This 67 
regulatory response is likely to contribute to parasitic worms being able to exist within their 68 
hosts for years, if not decades, without causing pathology. At the same time, the generation of 69 
an anti-inflammatory environment by parasitic worms has been considered to result in 70 
beneficial spill-over effects. Thus, a number of studies have demonstrated the ability of 71 
helminth infections, or molecules that helminths release (excretory-secretory products; E-S), 72 
 4 
to protect against, or ameliorate, both allergic diseases like asthma and autoimmune diseases 73 
such as rheumatoid arthritis, type-1 diabetes and inflammatory bowel disease (reviewed in [8-74 
10]). Furthermore, the observation that systemic inflammation plays a key role in the 75 
development of insulin resistance in obesity has led researchers to investigate, using mouse 76 
models, whether helminths can improve glucose tolerance and insulin sensitivity in obesity. 77 
Thus, for example, infection with Nippostrongylus brasiliensis [5], Schistosoma mansoni 78 
[11], Heligomosoides polygyrus [12] and Litomoisoides sigmondontis [13, 14] has been 79 
proven to improve insulin sensitivity in diet-induced mouse models of obesity. Similar effects 80 
were observed with treatment with helminth products. For example, Bhargava et al [15] 81 
demonstrated that LNFPIII, a component of S. mansoni, significantly improved glucose 82 
clearance and decreased extent of hepatosteatosis in obese mice. Additionally, it was found 83 
that schistosome [11] and Litomosoides [14] adult worm antigen extracts had the same 84 
protective effect as live worm infection. Helminth products have also been shown to play a 85 
disease-preventing role in murine models of atherosclerosis: for example, schistosome 86 
soluble egg antigen extract (SEA) treatment resulted in a 44% reduction in atherosclerotic 87 
plaque size in a cholesterol‐induced murine model of atherosclerosis [16]. 88 
 89 
ES-62, a phosphorylcholine (PC) containing glycoprotein secreted by the filarial nematode 90 
Acanthocheilonema viteae, has been shown to have protective effects in a number of 91 
autoimmune and allergic mouse models such as collagen-induced arthritis (CIA; [17]), the 92 
MRL/Lpr model of systemic lupus erythematosus (SLE; [18]) and the ovalbumin-induced 93 
airway hypersensitivity model of asthma ([19, 20]). Additionally, ES-62 reduces aortic 94 
plaques by almost 60% in the Gld.ApoE−/− mouse model of accelerated atherosclerosis, a 95 
cardiovascular condition often observed in SLE patients [21]. Although these results suggest 96 
that ES-62 could have widespread therapeutic potential, it constitutes a large, “foreign” and 97 
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hence likely immunogenic molecule that in addition, cannot be generated in active 98 
recombinant form [22] due to incomplete knowledge of the biosynthetic pathway responsible 99 
for addition of its active moiety, PC (reviewed by [23]). Thus, in case these factors should 100 
hamper its development towards the clinic, we have generated a library of PC-based small 101 
molecule analogues. Two of these SMAs, 11a and 12, have been shown to have similar 102 
protective effects to ES-62 in the mouse models of arthritis [24, 25], asthma [26, 27] and SLE 103 
[28]. The primary mechanism of action of the SMAs is the direct targeting of MyD88 for 104 
degradation that results in consequent downregulation of inflammation [29]. As MyD88 also 105 
interacts with the master metabolic sensor and highly conserved lifespan determinant, mTOR 106 
to integrate chronic inflammation, metabolic deregulation, oxidative stress and mitochondrial 107 
dysfunction [30-32], we wished to investigate whether the SMAs could positively impact on 108 
insulin resistance and adipose and liver tissue dysregulation in a diet-induced model of 109 
obesity. 110 
  111 
 6 
2. Methods  112 
2.1 Animals  113 
All the experimental procedures were approved by and conducted according to the Animal 114 
Welfare and Ethical Review Body at the University of Glasgow and UK Home Office 115 
Regulations and License PPL 60/4504. C57BL/6J mice (male and female; Charles River, 116 
UK) were divided into 3 groups: chow-fed-PBS-treated, HCD-fed PBS control, and HCD-fed 117 
SMA treated. The mice were injected once a week subcutaneously with PBS (control) or a 118 
combination of SMAs 11a plus 12b (1g of each) from 9 weeks old. All mice had ad libitum 119 
access to water and a chow diet (CRM-P; SDS, UK; Oil, 3.36%; Protein 18.35%; Fibre, 120 
4.23%: Sugar 3.9%; Atwater fuel energy from Oil, 9.08%; Protein, 22.03%: Carbohydrate, 121 
68.9%) plus 150 ppm Fenbendazole until 10 weeks of age. The HCD groups were then 122 
switched onto a western diet (HCD; Fat, 21.4%; Protein, 17.5; Fibre, 3.5%; Sucrose 33%; 123 
Atwater fuel energy from Fat, 42%; Protein, 15%: Carbohydrate, 43%; SDS, UK) plus 150 124 
ppm Fenbendazole. Mice were monitored daily and weighed weekly. Cohorts of mice were 125 
sacrificed at day (d)160 (n=4-6/group) and at d 340 (n=8/group) days of age and tissues were 126 
harvested. At d340 there was an additional group: HCD-fed SMA therapeutic (n=8; male and 127 
female). These mice were switched to a HCD at 10 weeks old but did not received SMA 128 
(11a+12b) injections until 23 weeks (d160) and again culled at d340.  129 
 130 
At sacrifice, the mesenteric lymph nodes (MLN) and retroperitoneal (dorsal fat pad directly 131 
behind the kidneys and attached to the peritoneum) adipose depots were recovered and 132 
prepared for flow cytometry analysis.  In addition, liver, adipose, ileum and colon tissues 133 
were fixed in 10% neutral buffered formalin, and embedded in paraffin, or flash frozen in 134 
OCT and stored at -80°C for future analysis.   135 
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2.2. Histology and Image Analysis  136 
Retroperitoneal adipose tissue was frozen in OCT and cryosectioned (ThermoScientific, UK) 137 
at 8-15 µm thickness at -30°C. Liver and gut tissues were embedded in paraffin and sectioned 138 
at 6 m. All tissues were stained with haematoxylin and eosin (H&E), and liver tissue 139 
sections were Gömöri’s Trichrome stained using previously described methods 140 
[33]. Brightfield images were captured using an EVOS FI Auto. Liver fat droplet deposition 141 
was calculated as the percentage “white area” (using a set threshold) relative to the total area 142 
of tissue in FOV in Volocity software, and collagen deposition was quantified as the 143 
percentage staining in FOV using ColourDeconvolution plugin and ImageJ software. 144 
Individual adipocyte area and adipocyte numbers in FOV of adipose tissue were calculated 145 
using Adipocount software (CSBIO). In the ileum and colon, the villi length (from crypt to 146 
tip) and crypt depth was measured using ImageJ software in 3 separate FOVs for each mouse 147 
and averaged.  148 
2.3 Flow Cytometry 149 
Retroperitoneal adipose tissue was digested in 1 mg/ml Collagenase type II (Sigma, UK) for 150 
45 minutes at 37C with gentle agitation and then passed through 100 M filter to generate 151 
the stromal vascular fraction (SVF). Red blood cells in MLN and SVF cell suspensions were 152 
lysed (eBioscience, UK); cells were then washed in FACS buffer (2.5% BSA; 0.5 mM 153 
EDTA, in PBS) and then incubated with Fc block (Biolegend, UK) prior to staining with the 154 
relevant antibodies/streptavidin conjugates (all BioLegend, UK unless stated otherwise). In 155 
adipose tissues, eosinophils were characterised as SiglecF+ (PE: Catalogue number 552126 156 
BD Bioscience, UK), and constitutive IL-10 expression was identified using anti-IL-10 157 
antibody (APC: catalogue number 505009). B regulatory cells in the MLN were identified by 158 
CD19 (AF700: Catalogue number 115527), B220 (PerCP: catalogue number 103235) and IL-159 
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10 (PE: Catalogue number 505007) expression [34]. Fixable viability stain (eFluor450: 160 
Catalogue number 65-0863-14; eBioscience, UK) was used to select for live cells. Data was 161 
acquired using a BD LSRII flow cytometer and populations were gated using isotype and 162 
fluorescence minus one (FMO) controls using FlowJo, LLC analysis software (Tree Star/ 163 
BD) as described previously [20, 34]. 164 
2.4. Glucose tolerance testing  165 
Mice were fasted overnight and their blood glucose level (nmol/L) was measured using an 166 
accu-check performa (Roche, UK) or OneTouch Ultra (Lifescan, UK) glucometer. Mice were 167 
then injected intraperitoneally with 20% glucose solution (2 g glucose/kg body weight) and 168 
their blood glucose levels were measured at 15, 30, 60 and 120 minutes-post injection, with 169 
blood samples obtained by caudal vein venesection.  170 
 171 
2.5. qRT-PCR 172 
Adipose tissue was lysed in QIAzol prior to mRNA extraction using the DNA away RNA 173 
extraction kit (NBS Biologicals, UK) and mRNA was transcribed into cDNA using the High 174 
Capacity cDNA Reverse Transcriptase kit (Applied Biosystems, Life Technology, UK). 175 
Changes in gene expression were measured using KiCqStart qPCR ready mix (Sigma-176 
Aldrich) and KiCqStart Primers on an Applied Biosystems Quant Studio 7. Data were 177 
normalized to the housekeeping gene -actin to obtain the CT values that were used to 178 
calculate the 2^-CT. Primer sequences were: -actin (forward-179 
GATGTATGAAGGCTTTGGTC, reverse-TGTGCACTTTTATTGGTCTC), IL-4 (forward- 180 
CTGGATTCATCGATAAGCTG, reverse- TTTGCATGATGCTCTTTAGG), IL-5 (forward-181 
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CCCTACTCATAAAAATCACCAG, reverse-TTGGAATAGCATTTCCACAG), TNF- 182 
(forward- CTATGTCTCAGCCTCTTCTC, reverse-CATTTGGGAACTTCTCATCC) 183 
TripBr2 (forward-CCACTTGTAACACACTCTTC, reverse- 184 
TCAACATTAGCAACACAGTC). 185 
2.6. Statistical Analysis  186 
All data was analysed using GraphPad Prism 6 or 8 software using two-way ANOVA (GTT), 187 
one-Way ANOVA (with Fishers LSD post-test for parametric data) or student’s t-tests. 188 
Significance is denoted by *p < 0.05, **p < 0.01 and ***p < 0.001.  189 
   190 
  191 
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3. Results 192 
3.1. SMA treatment reduces HCD-induced increased adipose tissue mass in male mice 193 
We investigated whether combination treatment with SMAs 11a plus 12b could have a 194 
positive impact on metabolic health in mice fed a high calorie diet (HCD), when compared to 195 
such mice given PBS and also PBS-treated chow-fed animals. Consumption of the HCD 196 
resulted in a significant increase in the body mass of both male and female mice by 160 days 197 
of age (Figure 1a), compared to their counterparts fed a standard chow diet. SMA, versus 198 
PBS, treatment had no significant effect on HCD-induced increased body mass of either male 199 
or female mice at 160 days of age (Figure 1a) and this was also the case at day 340 (results 200 
not shown). However, in male but not female mice, SMA administration slowed the HCD-201 
induced increase in retroperitoneal adipose depots (as a proportion of body mass) as 202 
evidenced by the reduction in the levels determined at 160 (Figure 1b), but not 340 (results 203 
not shown) days of age. Consistent with this finding, histological analysis revealed that SMA 204 
treatment similarly slowed the HCD-increase in retroperitoneal adipocyte size, as 205 
corroborated by quantitative analysis of the HCD-decrease in adipocyte numbers detected per 206 
field of view and also the HCD-enlargement of adipocyte area (albeit this last readout didn’t 207 
reach statistical significance) at day 160 (but not 340) in male but not female HCD-mice 208 
(Figure 1c-e and results not shown).  209 
3.2. SMA-treatment does not alter immunological parameters in adipose tissue 210 
In an attempt to understand the mechanism underlying the SMAs’ protective effects against 211 
HCD-induced changes in retroperitoneal adipose tissue in male mice at day 160, we 212 
measured a range of immunological parameters. Unlike the protection against metabolic 213 
changes induced by living parasitic worms described in previous studies [5, 35], SMA-214 
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protection in male mice did not appear to reflect a repolarisation of T-helper type-1/2 (Th-215 
1/2) inflammation as we did not observe any induction of eosinophils (Figure 2a) or 216 
increased production of mRNA for the Th-2 cytokines IL-4 and IL-5 (Figure 2b & c) when 217 
comparing PBS- versus SMA-treated, HCD-fed animals. Also, no effect on levels of anti-218 
inflammatory IL-10+ cells (Figure 2d), or expression of the pro-inflammatory cytokine TNF-219 
a (Figure 2e) was observed. Furthermore, we assessed expression of mRNA for the master 220 
regulator of adiposity, TripBr2 [36], but as with the immunological parameters, we did not 221 
see any SMA-induced effect (Figure 2f).  222 
3.3. SMA-treatment improves fasting glucose levels and impaired glucose clearance in 223 
male HCD-fed mice 224 
We next investigated the effect of HCD on the ability of mice to metabolise blood glucose, as 225 
retroperitoneal adipose tissue impacts on glucose tolerance with enhanced mass being 226 
associated with dysregulation of tissue function. We show that after 6-7 weeks of HCD (day 227 
116), fasted male mice had an impaired ability to clear blood-glucose compared to chow mice 228 
following administration of a bolus of glucose (glucose tolerance test; GTT): strikingly, this 229 
was converted back to chow-levels by treatment with SMAs 11a plus 12b (Figure 3a). 230 
Treatment with the SMAs also significantly lowered the fasting blood glucose levels of male 231 
mice at this time point (Figure 3b). Furthermore, the protective effect of SMA treatment on 232 
glucose clearance was still evident at 160 days of age, although somewhat diminished (Figure 233 
3c). Likewise, there remained some evidence of a protective effect on fasting glucose levels, 234 
as PBS-treated HCD-fed mice but not SMA-treated HCD-fed mice, showed significant 235 
glucose intolerance relative to chow-fed animals at this time point (Figure 3d). In contrast, 236 
the SMAs did not significantly modulate glucose clearance, or reduce fasting glucose levels, 237 
in HCD-fed female mice at either time point (Figure 3e & f and results not shown).   238 
 239 
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3.4. SMA treatment can improve some aspects of HCD-induced liver and gut pathology 240 
Chronic feeding with HCD can have a significant impact on liver function: increased free 241 
fatty acids - a result of insulin resistance - are deposited in the liver. This can cause 242 
inflammation and tissue disruption leading to the development of steatosis and fibrosis [3, 4]. 243 
Given that the SMAs ameliorated HCD-induced glucose intolerance in male mice (Figure 3) 244 
we measured various parameters associated with liver pathology. Histological analysis 245 
revealed that male mice in particular, when fed a HCD, did indeed exhibit steatosis by day 246 
160 (Figure 4a) but the SMAs did not protect against this in either sex at either day 160 or 247 
340 (Figure 4b & c and results not shown). Fibrosis, as indicated by collagen deposition, was 248 
also detected in the livers of both male and female mice fed a HCD by d160. For this 249 
pathology, the levels were similar between the two sexes and unlike for steatosis, the SMAs 250 
significantly protected against this in female HCD-fed animals at both time points (Figure 4d 251 
& e and results not shown).  252 
 253 
Continuous exposure to a HCD can also seriously impact on gut health and, consistent with 254 
this, we found histopathological evidence of ileal damage at d160 in both sexes (Figure 5a). 255 
Male PBS-treated HCD-fed animals revealed a significant decrease in villi length when 256 
compared to chow-fed animals, but this decrease was absent in the SMA-treated HCD-fed 257 
mice (Figure 5b). The decrease in villi length witnessed with female PBS-treated HCD-fed 258 
mice did not reach statistical significance, however, villi length in SMA-treated HCD-fed 259 
mice was significantly increased relative to the PBS-treated, HCD-fed mice and was 260 
comparable to that of chow-fed animals (Figure 5c).  No HCD-effects were observed in the 261 
colon at the same time-point (results not shown). Interestingly, we noted that damage to the 262 
ileum in both sexes was associated with a significant HCD-induced decrease in mesenteric 263 
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lymph node (MLN) regulatory B cells (Bregs; CD19+B220+IL-10+). However, SMA-264 
treatment did not significantly rebalance this (Figure 5d & e). 265 
 266 
3.5. SMA-treatment is protective when administered therapeutically to HCD-fed obese 267 
mice 268 
We next investigated whether the combination of SMAs 11a and 12b had any protective 269 
effect in a therapeutic situation, namely when their administration was delayed until ~13 270 
weeks after the start of the HCD (day 160) and assessment undertaken following a further 271 
180 days of HCD feeding and treatment with SMAs. As observed at day 160 and day 340 272 
with prophylactic SMA treatment, there was no significant effect of the treatment on body 273 
mass of either male or female mice (Figure 6a). However, unlike with the prophylactic model 274 
at day 160 (but not 340), therapeutic SMA administration from day 160 had no effect on the 275 
size of the retroperitoneal adipose depots in male (and also female) HCD-fed animals at 340 276 
days of age (Figure 6b).  This was supported by histopathological analysis, which showed 277 
that SMAs (when administered either prophylactically or therapeutically) had no significant 278 
effect on either the number or average adipocyte area of adipocytes (per field of view) in 279 
retroperitoneal adipose tissue when compared to HCD-PBS mice at d340 (Figure 6c-e, and 280 
results not shown). Moreover, as shown by the GTT-time course, by day 340 glucose 281 
tolerance had undergone a remodelling process in male HCD-fed mice such that it is removed 282 
more rapidly from the circulation relative to the younger cohort (Figure 7a), possibly due to 283 
the increased capacity to take-up glucose provided by their enlarged visceral adipose tissues 284 
[37]. Interestingly, treatment with 11a plus 12b (either prophylactically or therapeutically) 285 
significantly reversed this remodelling such that the glucose clearance in SMA-treated HCD-286 
fed male mice more resembled that of chow-fed mice (Figure 7a and results not shown). 287 
Nevertheless, whilst fasting glucose levels were increased in the PBS-treated HCD-fed male 288 
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animals relative to chow-fed mice, this was significantly reduced by therapeutic SMA-289 
treatment (Figure 7b). Collectively these data suggest that the SMAs support “chow-like” 290 
glucose handling throughout d116-d340 in male mice, despite the chronic exposure to HCD 291 
from d70. Female mice do not experience the HCD-induced glucose metabolism remodelling 292 
observed with male mice at the 340-day time-point as shown by the GTT and hence HCD-fed 293 
mice still show increased persistence in the bloodstream relative to chow-fed animals (Figure 294 
7c). However, unlike the situation at day 116 and 160 with prophylactic treatment, SMA-295 
treated HCD-fed female mice show a significant improvement in glucose clearance following 296 
therapeutic treatment with SMAs (Figure 7c) although perhaps surprisingly this was not 297 
accompanied by a modulation of fasting glucose levels (Figure 7d). Also, we did not observe 298 
any improved glucose clearance with female mice at day 340 in the prophylactic model 299 
(results not shown).  300 
 301 
We also examined liver fibrosis following therapeutic administration of the SMAs: as with 302 
the prophylactic models (d160, Figure 4 and d340, data not shown), we observed a 303 
statistically significant protective effect against the HCD-induced collagen deposition but not 304 
steatosis in female but not male mice (Figure 8 and results not shown). In addition, unlike at 305 
day 160, we observed HCD-induced colon damage in male (but not female; results not 306 
shown) mice as revealed by a significant decrease in crypt depth between chow-fed and PBS-307 
treated HCD-fed mice. However, this significance was absent between chow-fed and HCD-308 
fed animals treated with the SMAs either prophylactically (data not shown) or therapeutically 309 
at d340 (Figure 9a & b). Focusing on mechanism of action again, we also measured MLN 310 
Bregs at this time point: as observed earlier, these were reduced by HCD but SMA-treatment 311 
(either prophylactically or therapeutically) did not reverse this (Figure 9 and results not 312 
shown). 313 
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4. Discussion 314 
 315 
Emerging evidence suggests that parasitic worm infection can have positive effects on 316 
metabolic regulation. This has led to the idea that the worms might be exploited as a 317 
treatment against obesity, a rapidly increasing global health problem that can result in a 318 
number of serious health conditions such as type-2 diabetes, for which current treatment 319 
approaches result in unwanted side effects. This evidence is largely derived from studies 320 
employing mouse models of obesity, in which parasitic worms or their molecules have been 321 
shown to improve glucose tolerance [5, 11, 13, 14]. Moreover, it has also been shown that 322 
humans infected with gastrointestinal nematodes develop increased insulin resistance 323 
following treatment with an anthelmintic [38].  We now provide further support for the 324 
protective effects of worms when employing two synthetic small molecule analogues (SMAs) 325 
of ES-62, a major secreted protein of A. viteae that is immunomodulatory by virtue of 326 
multiple covalently attached phosphorylcholine (PC) residues [reviewed in [8] and [39]], in a 327 
C57BL/6J mouse model of obesity. We employed the SMA combination because although 328 
both compounds are protective in mouse models of diseases associated with aberrant 329 
inflammation like rheumatoid arthritis, they show subtle differences in immunomodulatory 330 
mechanism of action [24, 25]. Like the parent molecule, the SMAs appear to be safe as 331 
evidenced by our administration of them to mice on a weekly basis for 9-10 months with no 332 
adverse effects noted during careful monitoring in this study and consistent with this, we had 333 
previously witnessed no toxic effects in vitro when assessing staining of macrophages with 7-334 
AAD or worsening of inflammatory disease in vivo in acute (1-2 months) mouse models [24, 335 
25]. As the SMAs are also cost-effective and straightforward to produce, they represent an 336 
attractive starting point for novel drug development.  337 
 338 
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As expected, exposure to a HCD, resulted in a significant increase in body mass in both male 339 
and female mice. SMA-treatment did not protect against this increase. However, there were 340 
some indications that the molecules were having more-subtle beneficial effects, in that HCD-341 
induced changes occurring in visceral adipose tissue were somewhat reduced in male mice 342 
exposed to the SMA- versus PBS-treatment at day 160. Previous studies using live worm 343 
infection have provided mixed results when examining effects on whole body and adipose 344 
tissue mass [11-14] but this may in part reflect worm species differences and/or variation in 345 
experimental design. The reduction in adipose tissue mass that we witnessed was associated 346 
with male mice only and was no longer present by day 340. Considering the known 347 
association between increased body mass and decreased glucose homeostasis, we went on to 348 
examine whether the SMAs would affect glucose handling. HCD treatment resulted in 349 
impaired glucose tolerance and this was observed at both day 116 and 160 in the male mice. 350 
Data from the GTT analysis showed that SMA-treatment significantly protected against 351 
impaired HCD-induced glucose intolerance and fasting plasma glucose levels were also 352 
lower in SMA-treated mice at both ages. These effects were more apparent at the earlier time 353 
point initially leading us to consider that with respect to glucose clearance, the SMAs may 354 
eventually struggle to be effective as metabolic dysfunction progresses. However, remarkably 355 
by the time the HCD-fed mice have reached 340 days of age, they can remove glucose from 356 
the circulation even more effectively than chow-fed mice and perhaps somewhat ironically 357 
the SMA-treatment actually converts the GTT values back towards the chow-fed phenotype. 358 
This remodelling effect has been described previously [37]: it is considered to be due to 359 
increased glucose uptake via enlarged visceral adipose tissues and may help protect the body 360 
against further obesity-induced damage. Presumably it is less obvious in SMA-treated mice 361 
because overall, they develop less visceral adipose tissue (we only examined retroperitoneal 362 
adipose tissue) or at least the increase is delayed, as shown in the present study for 363 
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retroperitoneal tissue. Interestingly, overall the SMAs appear to be more effective than ES-62 364 
in dealing with rising blood glucose levels although we did not test the early day 116 365 
timepoint with the parent molecule [40]. We did not observe any protective effect of the 366 
SMAs on glucose clearance in female mice in the current study but such animals appear to 367 
show somewhat less impairment of this in response to HCD than males.  368 
 369 
We also determined the effects of SMA-treatment on a number of other HCD-induced 370 
pathological alterations – liver steatosis and fibrosis, gut ileum and colon damage. We found 371 
no protection against steatosis but reduced fibrosis in both sexes, although this was only 372 
statistically significant in female mice. These data for both steatosis and fibrosis mirror what 373 
we observed when treating HCD-fed mice with ES-62 [40], although with the parent 374 
molecule, protection against fibrosis in the male mice also reached statistical significance. 375 
Nevertheless, returning to steatosis, H. polygyrus can markedly improve this in diabetic mice 376 
[12, 41], indicating different effects from the ES-62-SMAs. Regarding gut damage, we found 377 
evidence of HCD-induced ileum damage (reduced villus length at d160) that was protected 378 
against by SMA treatment, particularly in female animals. Again, these gut data largely 379 
mirror what we have observed with ES-62 [40].  380 
 381 
The protection observed with the SMAs in what effectively is a prophylactic model, supports 382 
their use as a potential preventive medicine against the health conditions associated with 383 
obesity. However, another more likely option would be to employ the compounds as a 384 
therapeutic and with this in mind, we investigated whether the SMAs still offered any 385 
protective effects when their administration was delayed until approximately 13 weeks after 386 
the start of the HCD (day 160). With this therapeutic administration, we did not observe any 387 
effect on retroperitoneal adipose tissue. The SMA treatment did however result in glucose 388 
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clearance showing a chow-like rather than HCD-like phenotype and this was also true of 389 
fasting glucose levels. Interestingly, in the therapeutic model at day 340 when examining 390 
female mice, which do not undergo the remodelling of glucose handling observed in their 391 
male counterparts, for the first time we found some evidence of protection against impaired 392 
glucose clearance. However, there was no improvement in fasting glucose levels in these 393 
animals. Female mice undergoing the prophylactic regimen did not reveal any protection at 394 
the same day 340-time point. Thus overall, the female situation with respect to glucose 395 
homeostasis is rather less clear-cut than the male. Interestingly however, as observed with 396 
prophylactic SMA administration, therapeutically-treated female mice appear to suffer less 397 
liver fibrosis. Overall, it is encouraging that both sexes appear to respond to SMA treatment 398 
in a therapeutic setting in some manner, raising the possibility that SMA-based drugs might 399 
be considered for use in this manner in male and female humans. Nevertheless, on the whole,  400 
the differences between the two sexes that we observe are intriguing in that they suggest both 401 
that male and female mice may suffer differing degrees of particular obesity-induced 402 
pathologies and also, register differences in the ability of the SMAs to prevent the 403 
pathologies. Possibly at least some of the variation we have observed with respect to both 404 
factors could relate to sex-specific differences in hormone levels and it could therefore be 405 
interesting to investigate the effects of hormonal intervention in our system. We have also 406 
observed sex-specific responses to ES-62 treatment with this model [40] but as far as we are 407 
aware, this has not been reported with other defined helminth-derived molecules that are 408 
protective in mouse models of inflammatory diseases.  409 
 410 
To date, we have obtained a significant amount of mechanistic data when employing the 411 
SMAs in mouse models of allergy and autoimmunity. Thus, for example, we have found that 412 
like ES-62, the SMAs reduce the production of cytokines that are important in driving the 413 
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inflammatory response [24, 25, 27], reset the effector: regulatory B cell balance to the non-414 
inflammatory situation [27, 28] and promote degradation of the TLR adaptor MyD88 [29]. In 415 
the present study, we undertook mechanistic analysis based on previously published papers 416 
outlining how parasitic worms helped maintain glucose homeostasis. Thus, for example, Wu 417 
et al. [5] showed that homeostasis in adipose tissue was dependent on AAMs induced by IL-4 418 
released from eosinophils and thus, that infection with N. brasiliensis, by increasing levels of 419 
adipose tissue eosinophils, could protect against obesity-induced impaired homeostasis. 420 
Likewise, protection offered by L. sigmodontis is associated with increased eosinophils and 421 
AAMs in adipose tissue [14]. However, when investigating retroperitoneal adipose tissue 422 
from male animals at the day 160 time point we did not witness any change in levels of 423 
eosinophils or mRNA for IL-4 or the related cytokine that plays multiple roles in eosinophil 424 
biology, IL-5 in adipose tissue. Likewise, taking into account the known increased 425 
inflammatory nature of adipose tissue from HCD-fed mice we measured levels of the anti-426 
inflammatory IL-10-producing cells and the pro-inflammatory cytokine TNF- but SMA-427 
treatment did not increase the former or reduce the latter. One possible explanation for these 428 
results is that we may be past the point where SMA-protection is optimal in the model, as 429 
when examining the GTT data the SMAs appeared to be more effective at day 116 than day 430 
160. Thus, examining day 116 tissue for immune cell and cytokine profiles during this earlier 431 
time point may be warranted. Nevertheless, in spite of detecting some reductions in 432 
inflammatory- and increases in anti-inflammatory-markers in the ES-62 study referred to 433 
earlier [40], these changes did not appear to be the key factors that improved healthspan or 434 
lifespan in ageing animals. Rather a more convincing case – supported by a machine learning 435 
approach – was provided by metabolic changes and improved gut health/reduced gut 436 
dysbiosis. Furthermore, although an increase in adipose tissue IL-10 was observed with 437 
protective H. polygyrus infection [12, 41], Berbudi et al. [14] did not observe a role for this 438 
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cytokine when observing protective effects with L. sigmodontis. In any case, the protective 439 
effects we observe on retroperitoneal adipose tissue could be related to other non-440 
immunological factors. We thus examined levels of mRNA for TRIP-Br2, a transcription 441 
factor that regulates fat lipolysis: TRIP-Br2’s expression is elevated in visceral fat in obese 442 
humans and in addition, knockout mice are resistant to obesity-induced insulin resistance 443 
[36].  However, we did not observe any reduction in TRIP-Br2 expression. Nevertheless, 444 
there are a number of other genes involved in glucose homeostasis that might be worth 445 
examining: in particular, these might include glucose transporters (considered to be drug 446 
targets in Type-2 diabetes) such as GLUT2 and GLUT4, whose expression is modified by H. 447 
polygyrus [12] and L. sigmodontis respectively [14]. 448 
 449 
We also observed that the HCD-induced gut damage was associated with a decrease in MLN 450 
Bregs but that the SMAs could not reverse this. Although we have previously observed that 451 
the SMAs can overturn alterations in the effector: regulatory B cell balance, our work with 452 
ES-62 indicates that changes in Bregs are dynamic and may only occur during certain 453 
checkpoints throughout the disease model [27, 40]. In any case, a further study should 454 
investigate whether we are actually witnessing downregulation of MyD88 in immune system 455 
and tissue effector cells when the SMAs are employed in the model, given the uniformity of 456 
this event with difference cell types exposed to ES-62/SMAs to date, including effector B 457 
cells [18, 24, 25, 27]. We did not examine levels of T regs (CD25+FoxP3+) or Tr1 (IL-458 
10+CD4+) cells as our experience from a number of mouse models of allergic [27] and 459 
autoimmune [18] diseases is that ES-62 does not induce such cells. In any case, Tregs 460 
appeared to play no role in L. sigmodontis-protection against impaired glucose clearance 461 
although increased Foxp3 expression was observed in MLN cells during protective H. 462 
polygyrus infection [12, 41].  463 
 21 
 464 
A final factor, which needs to be considered when investigating the mechanism of action of 465 
the SMAs in ameliorating glucose intolerance is the microbiome. It has recently been shown 466 
[42] that Strongyloides venzuelensis improves insulin sensitivity and signalling in mice by 467 
impacting on the composition of the gut microbiome. Although this is associated with 468 
induction of an anti-inflammatory environment in adipose tissue, which we have not 469 
witnessed with the SMAs in the current study, we have recently found ES-62 to also 470 
modulate the composition of the mouse gut microbiome during both HCD-accelerated ageing 471 
[40] and collagen-induced arthritis [34]. We now plan to establish whether a similar situation 472 
occurs with SMA-treatment. 473 
 474 
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Figure Legends 478 
 479 
Figure 1: SMAs reduce adipocyte hypertrophy in male HCD-fed mice. Data in panels a 480 
and b are presented as the values of individual mice. (a) PBS- and SMAs-treated HCD-male 481 
(Blue; ***p<0.001) and -female (Red; *p<0.05) mice exhibited substantially higher Body 482 
Mass (BM) than their aged-matched chow (also PBS-treated) control groups. In addition, the 483 
male mice were significantly heavier at cull than their female counterparts (chow, **p<0.01, 484 
PBS, ***p<0.001). (b) Analysis of retroperitoneal fat (% BM) of chow, PBS- or SMAs-485 
treated HCD mice at cull, where *p<0.05 for male HCD-SMAs versus HCD-PBS mice. 486 
Representative images (scale bar 100 m) of retroperitoneal fat from male chow- and HCD- 487 
mice stained with H & E (c) and resultant quantitative analysis of adipocyte number (d) and 488 
size (e) where d160 data are presented as the mean values (derived from n=3 replicate 489 
analyses) for individual mice where, *p < 0.05 for HCD-PBS versus HCD-SMAs mice. The 490 
p value for male HCD-PBS versus HCD-SMAs is shown on the figure in panel e. For Chow 491 
mice, n=2 due to the very limited amounts of retroperitoneal tissue recovered from these lean 492 
male mice.  Statistical analysis is by one-way ANOVA or student’s t-test. 493 
 494 
Figure 2: SMAs do not modulate the Th1/Th2 balance in retroperitoneal adipose tissue 495 
in male HCD-fed mice. The levels of SiglecF+ eosinophils (% live SVF cells) from 496 
retroperitoneal adipose tissue of PBS- and SMAs-treated mice are presented for individual 497 
animals in each cohort (a). qRT-PCR analysis of IL-4 (b) and IL-5 (c) mRNA expression in 498 
retroperitoneal fat from male PBS- and SMAs-treated mice where data are expressed as 2CT 499 
values of individual mice and where the values for each mouse are means of n=3 replicate 500 
analyses. (d) The levels of IL-10+ cells (% live SVF cells) in retroperitoneal fat in male PBS- 501 
and SMAs-treated mice in the d160 cohorts are shown. qRT-PCR analysis of TNF (e) and 502 
TripBr2 (f) mRNA expression in retroperitoneal fat from male PBS- and SMAs-treated mice 503 
where data are expressed as 2^CT values of individual mice and where the values for each 504 
mouse are means of n=3 replicate analyses. 505 
 506 
Figure 3: SMAs modulate glucose handling in male HCD-fed mice. Glucose tolerance 507 
tests (GTT) were undertaken at d116 (a - male, e - female) and one week before the d160 cull 508 
(c - male, f- female) with fasting glucose measured at d116 (b) and at d160 cull (d) in male 509 
mice. GTT data are presented as mean values ± SEM of individual male (d116, chow n=8; 510 
PBS n=6; SMAs n=8; d160 cull, chow n=4; PBS n=6; SMAs n=6) and female (d116, chow 511 
n=6; PBS n=5; SMAs n=8; d160 cull, chow n=4; PBS n=6; SMAs n=5) mice at each time 512 
point, where *p<0.05 and ***p<0.001 for HCD-PBS versus HCD-SMAs by two-way 513 
ANOVA (a, c) and *p< 0.05 for HCD-PBS versus HCD-SMAs or chow by one-way 514 
ANOVA (b, d).  515 
 516 
Figure 4: SMAs reduce liver fibrosis. (a) Representative images (scale bar 100 µm) of liver 517 
from male and female mice stained with Gömöri’s Trichrome: quantitative analysis of fat (b 518 
& c) and collagen deposition (d & e) is presented as mean (of triplicate analyses) values of 519 
individual male (b & d) and female (c & e) mice. Significant difference between the HCD-520 
PBS and HCD-SMAs cohorts is shown where *p < 0.05 by one-way ANOVA.  521 
 522 
Figure 5: SMAs ameliorate gut pathology. (a) Representative images (scale bar 500 µm) of 523 
ileum tissue from male and female chow- and HCD- (PBS- or SMAs-treated) d160 mice 524 
stained with H & E (upper panels) and Gömöri’s Trichrome (lower panels). Quantitative 525 
analysis of ileum villus length (b, c) are shown. Data are presented as the mean values for 526 
individual mice, where the values for each mouse are means derived from n=3 replicate 527 
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analyses and where *p<0.05 for HCD-PBS versus Chow (b) and HCD-SMAs (c). (d, e) MLN 528 
IL-10+ Bregs (B220+CD19+IL-10+; % live cells) are presented as the values for individual 529 
male (d) and female (e) mice and where **p<0.05 and ***p<0.001 for chow versus HCD-530 
PBS (and female HCD-SMAs) mice by one-way ANOVA or student’s t-test.  531 
 532 
Figure 6: Therapeutic treatment with SMAs from d160 (SMAsT) does not reduce 533 
adipocyte hypertrophy in HCD-fed mice at d340. (a) HCD-male (Blue; ***p<0.001) and -534 
female (Red; **p<0.01) mice exhibited substantially higher Body Mass (BM) than their 535 
aged-matched chow control groups. In addition, male mice were significantly heavier at cull 536 
than their female counterparts (chow, ***p<0.001, PBS, ***p<0.001, where data are from 537 
individual mice). (b) Analysis of retroperitoneal fat (% BM) of chow, PBS- or SMAsT-538 
treated HCD mice at cull where data are presented as the values of individual mice, and 539 
**p<0.01 for HCD-PBS versus chow mice. Representative images (scale bar 100 µm) of 540 
retroperitoneal fat (c) from female chow- and HCD- (PBS- or SMAsT-treated) mice stained 541 
with H & E and resultant quantitative analysis of adipocyte size where data are presented as 542 
the mean values (derived from n=3 replicate analyses) for individual mice where, *p < 0.05 543 
and ***p<0.001 for HCD-PBS versus chow mice by one-way ANOVA.  544 
 545 
Figure 7: Therapeutic treatment with SMAs modulates glucose handling in HCD-fed 546 
mice. Glucose tolerance tests (GTT) were undertaken one week before the d340 cull (a, c) 547 
with fasting glucose measured at cull (b & d). GTT data are presented as mean values ± SEM 548 
of individual male (n=8 all cohorts) and female (chow n=6; PBS n=7; SMAsT n=8) mice at 549 
each time point, where *p<0.05, **p<0.01 and ***p<0.001 for HCD-PBS versus HCD-550 
SMAsT by two-way ANOVA (GTT) or one-way ANOVA (fasting glucose). 551 
 552 
Figure 8: Therapeutic treatment with SMAs reduces liver fibrosis in female HCD-fed 553 
mice at d340. (a) Representative images (scale bar 100 µm) of liver from male and female 554 
mice stained with Gömöri’s Trichrome: quantitative analysis of collagen deposition (b & c) is 555 
presented as mean (of triplicate analyses) values of individual male (b) and female (c) mice. 556 
Significant difference between the HCD-PBS and HCD-SMAsT cohorts is shown where *p < 557 
0.05 by one-way ANOVA.  558 
 559 
Figure 9: Therapeutic treatment with SMAs reduces colon damage in male HCD-fed 560 
mice at d340. (a) Representative images (scale bar 500 µm) of colon tissue from male chow- 561 
and HCD- (PBS- or SMAsT-treated) mice at d340 stained with H & E (upper panels) and 562 
Gömöri’s Trichrome (lower panels) and quantitative analysis of crypt depth (b) are shown. 563 
Data are presented as the mean values of individual male mice, where the values for each 564 
mouse are means derived from n=3 replicate analyses and *p<0.05 for HCD-PBS versus 565 
Chow. (c) MLN IL-10+ Bregs (B220+CD19+IL-10+; % live cells) are presented as the values 566 
for individual male mice, where *p<0.05 for HCD-PBS versus chow mice by one-way 567 
ANOVA. 568 
 569 
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